CD20 chimeric antigen receptor mRNA

CD20 chimeric antigen receptor (CAR) mRNA refers to a therapeutic modality where messenger RNA encoding a CAR specific for the CD20 antigen is delivered to immune cells, typically T cells or natural killer (NK) cells. Unlike traditional CAR-T therapies that use viral vectors (such as lentivirus or retrovirus) to achieve permanent genomic integration and constitutive CAR expression, mRNA-mediated delivery results in transient expression of the receptor. This temporary expression, typically lasting only a few days, offers a significant safety advantage by allowing for the mitigation of long-term toxicities such as B-cell aplasia or severe cytokine release syndrome. The mRNA can be introduced into cells *ex vivo* via electroporation or *in vivo* using lipid nanoparticle (LNP) delivery systems. This platform is primarily investigated for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), where transient but potent B-cell depletion is desired.

Other names

CD20 CAR mRNACD-20 CAR mRNACD 20 CAR mRNAmRNA-encoded CD20 CARmRNA-transfected CD20 CAR-T